IP Library › Granted Patent US 11,135,173
Granted Patent B2
US 11,135,173 · App. 16/084,308 · Granted Oct 5, 2021

Prolonged release pharmaceutical composition comprising cysteamine or salt thereof

Inventors: Andrea Gazzaniga (Santa Giuletta, IT); Matteo Cerea (Grumello del Monte, IT); Alessandra Maroni (Luvinate, IT); Marco Barchielli (Arese, IT)
Assignee: RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A.
A61K9/5026A61K9/5015A61K9/5042A61K31/145
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,135,173
App. No.
16/084,308
Granted
Oct 5, 2021
Kind
B2
Abstract

A prolonged release multiple unit dosage form, preferably pellets, of cysteamine, cystamine or a pharmaceutically acceptable salt thereof, preferably cysteamine bitartrate, with a non gastro-resistant coating is described. The dosage form is particularly indicated for the administration to patients once or twice a day and it can be used also for pediatric administration.

Claims (24)

1. A prolonged release dosage form comprising:

a multiple unit dosage form,

each of the multiple units consisting of a pellet with a solid core formed from a mixture of cysteamine bitartrate and a spheronization agent selected from the group consisting of microcrystalline cellulose, starch, hypromellose and crospovidone,

wherein each of the multiple units of the multiple unit dosage form has a non gastro-resistant coating, and

wherein the non gastro-resistant coating consists of a polymer material which is non-hydrosoluble, or has a non pH-dependent aqueous solubility,

wherein the non gastro-resistant coating is optionally in admixture with one or more components selected from the group consisting of plasticizers, non-sticking agents and canalizing agents.

2. The dosage form according to claim 1 , wherein the polymer material is selected from the group consisting of polyvinyl acetate; ethylcellulose; cellulose acetate; poly(ethylacrylate-co-methylmethacrylate-co-trimethylammoniumethyl methacrylate chloride) 1:2:0.1, poly(ethylacrylate-co-methylmethacrylate-co-trimethylammoniumethyl methacrylate chloride) 1:2:0.2 and poly(ethylacrylate-co-methylmethacrylate) 2:1; hydroxypropyl methylcellulose; hydroxypropyl cellulose; hydroxyethyl cellulose; polyvinyl alcohol; and polyethylene oxide.

3. The dosage form according to claim 1 , wherein the plasticizer is selected from the group consisting of propylene glycol, triethyl citrate, acetyl tributyl citrate, acetyl triethyl citrate, benzyl benzoate, ricin oil, chlorbutanol, diacetyl monoglycerides, dibutyl sebacate, diethyl phthalate, glycerine, mannitol, polyethylene glycol, polyethylene glycol monomethyl ether, pullulan, sorbitol, sorbitol sorbitan solution, triacetin, tributyl citrate, and vitamin E.

4. The dosage form according to claim 1 , wherein the canalizing agent is selected from the group consisting of polyvinyl alcohol-polyethylene glycol copolymer and hydroxypropyl methylcellulose.

5. The dosage form according to claim 1 , wherein the coating consists of a mixture of polyvinyl acetate, propylene glycol and polyvinyl alcohol-polyethylene glycol copolymer.

6. The dosage form according to claim 1 , wherein the coating represents a weight gain of the uncoated multiple units from 10% to 60% by weight.

7. The dosage form according to claim 2 , wherein the polymer material is polyvinyl acetate or ethylcellulose.

8. The dosage form according to claim 3 , wherein the plasticizer is propylene glycol.

9. The dosage form according to claim 6 , wherein the coating represents a weight gain of the uncoated multiple units from 15 to 30% by weight.

10. The dosage form according to claim 1 , wherein the cysteamine bitartrate and the spheronization agent are in a weight ratio of 70:30 to 90:10.

11. The dosage form according to claim 1 , wherein each pellet has a particle size between 700 μm and 1400 μm.

12. The prolonged release dosage form of claim 1 , wherein the cysteamine bitartrate is released from the dosage form in a non-pH dependent manner and without a peak effect.

13. The prolonged release dosage form of claim 1 , wherein the non-sticking agent is talc.

14. A prolonged release dosage form comprising of:

a multiple unit dosage form,

each of the multiple units being a pellet consisting of a solid core formed from a mixture of cysteamine bitartrate and a spheronization agent being microcrystalline cellulose,

wherein each of the multiple units of the multiple unit dosage form has a non gastro-resistant coating,

wherein the non gastro-resistant coating is in admixture with a plasticizer, a non-sticking agent, and a canalizing agent and,

wherein the non-gastro-resistant coating is polyvinyl acetate, the plasticizer is propylene glycol, the non-sticking agent is talc, and the canalizing agent is a polyvinyl alcohol-polyethylene glycol copolymer.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 12, 2018
From: GAZZANIGA, ANDREA; CEREA, MATTEO; MARONI, ALESSANDRA; BARCHIELLI, MARCO
To: RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A.
Reel/Frame 046849/0142 →
Priority Claims (1)
IT UA2016A001799 · Mar 18, 2016 · national
Continuity (1)
Related Publication 20190076368A1 · Mar 14, 2019